After acquiring Applikon Biotechnology in 2020, Getinge says it is focused on serving the bioprocess space as it does the medical tech industry. “Getinge has 90% of its business going into hospitals, like ventilators or operating rooms, but we also have a life sciences unit and we have acquired Applikon in January 2020 to become part of that business unit,” Matthijs Niemeijer, head of Product Management at Getinge told BioProcess Insider at BPI Boston, part of Biotech Week Boston. Applikon…
Thursday, September 29, 2022 Daily Archives
BASF leveraging chemical heritage in bio excipient space
Chemical giant BASF says owning its own manufacturing facilities gives it full control of volume and chemistry and is a differentiator in the biopharma ingredients space. As the world’s largest chemical firm, it is no surprise BASF plays in numerous markets. In biopharma, the firm is known for its small molecule active pharmaceutical ingredient (API) business but the German multinational also serves the biologics manufacturing space. “For a few years we have been providing the biomanufacturing industry with our products…
Cytiva: Standardization key to fluid management prowess
Standardization is critical to improve fluid management operations within a biomanufacturing facility, says Cytiva at BPI Boston. “Fluid management, while it’s not one of the most technically complex parts of bioprocess, it’s one of the more logistically complex aspects,” Erik Storm, fluid management platform leader at Cytiva, told BioProcess Insider at BPI Boston – part of Biotech Week Boston. “That’s because of the large number of parts that you have to have on hand to actually run a single-use facility.…
Platforms are pivotal to pandemic speed, says BMS
Only companies that have strong platforms will be able to meet specific timelines, says Bristol-Myers Squibbs’ Jim Xu. As COVID-19 transitions into an endemic, delegates at Biotech Week Boston discussed the challenges concerning the upstream process development process. Jianlin (Jim) Xu, scientific director, biologics development at BMS, explained told a packed room that monoclonal antibodies (mAbs) are difficult to produce with complex glycosylation profile, process related impurities, and amino acid oxidation. Xu also outlined other challenges, which included bioreactor operation…